NCT05669001: An ongoing trial by ITB-Med LLC
This trial is ongoing. It must report results 1 year, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05669001 |
|---|---|
| Title | A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 28, 2023 |
| Completion date | April 30, 2026 |
| Required reporting date | April 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |